Careers

Engagement Manager — Life Sciences

Taipei — Hybrid ｜ Full-time

ABOUT THE ROLE

The Engagement Manager is AGMI’s operational lead for client engagements in the life science sector. You will lead a team of 3-5 consultants, scoping and managing project workstreams spanning commercial strategy, BD and licensing, investment due diligence, and market entry across biotech, pharmaceutical, and medtech clients. You will translate Partner-defined objectives into structured execution, hold the team to the standard the work requires, and serve as the primary point of contact for clients throughout an engagement.

Developing the people on your team is as central to this role as the client work itself. You will be expected to bring both scientific or commercial domain literacy and the consulting craft to turn it into structured, client-ready insight.

Candidates with a background at a management consultancy or in life science corporates, investment firms, or healthcare-focused strategy functions are equally valued.

KEY RESPONSIBILITIES

Engagement Leadership

  • Own end-to-end delivery of life science engagements from kick-off through final presentation, ensuring quality, accuracy, and timeline adherence
  • Translate Partner-defined objectives into structured project plans with clear workstreams, milestones, and ownership across the team
  • Decompose complex mandates such as pipeline valuation, licensing strategy, and market access assessment into discrete tasks and allocate work to Associates
  • Maintain an integrated view of all workstreams, proactively identifying risks, interdependencies, and analytical gaps before they become problems

Team Management & Mentorship

  • Lead, coach, and develop Associates on both technical skills and consulting craft, including modelling, research, slide logic, storylining, and client communication
  • Conduct regular check-ins to monitor progress, resolve blockers, and ensure output quality before client submission
  • Foster a team culture of intellectual rigour, scientific curiosity, and continuous professional growth

Client Communication & Stakeholder Management

  • Serve as the primary day-to-day client contact, managing expectations and maintaining strong professional relationships throughout the engagement
  • Lead working sessions, interim reviews, and executive-level presentations; synthesise client feedback and cascade adjustments to the team
  • Manage upward to Partners with timely status updates, decision escalations, and strategic alignment
  • Navigate multi-stakeholder environments including biopharma corporates, venture investors, regulatory bodies, and academic institutions

Strategic Advisory

  • Contribute substantive life science domain expertise to engagement strategy alongside Partners
  • Advise clients on commercial strategy, partnership and licensing structures, M&A targets, and market positioning
  • Identify opportunities to expand engagement scope or develop new client relationships in collaboration with the business development team
  • Stay current on clinical pipelines, regulatory approvals, deal flow, and innovation trends across the life science landscape

QUALIFICATIONS

REQUIRED

  • 3–7 years of progressive experience in management consulting, investment banking, or corporate strategy, with a minimum of 2 years leading teams or projects in a life science context
  • Demonstrated track record of managing end-to-end consulting or advisory engagements in biotech, pharma, or medtech
  • Strong command of project management disciplines including task decomposition, milestone tracking, resource allocation, and cross-functional coordination
  • Excellent written and verbal communication skills; comfortable presenting to C-suite, board, or investment committee audiences
  • Business-level fluency in both Mandarin Chinese and English, written and spoken

PREFERRED

  • Consulting experience at MBB, Big Four advisory, or a specialist life science strategy firm
  • Alternatively, a strategy or BD leadership role at a biopharma, medtech, or life science investment firm
  • Advanced degree strongly preferred: MBA, PhD in life sciences, MD/MBA, or equivalent
  • Experience in licensing, M&A, market access, or go-to-market strategy for innovative therapeutics or devices
  • Proficiency in Japanese or other languages
  • Familiarity with North America, Asia-Pacific life science regulatory and investment environments

WORK ARRANGEMENT

This is a remote-first role. You will be expected to travel to client sites, domestically and internationally, based on engagement needs. 

HOW TO APPLY

Ready to apply?

To submit your application, please click the button below

Apply Now

For any enquiries, please contact us at [email protected] 

Stage 01

CV & Profile Review

Stage 02

Take-home Case Study

Stage 03

Case Presentation

Stage 04

Personal Experience Interview

ABOUT AGMI GROUP

Born at the intersection of science and strategy.

AGMI Group was born from a shared vision among seasoned leaders, many of whom honed their deep domain expertise in the Life Sciences and Technology through PhDs, and their strategic acumen at consultancy firms like McKinsey & Co. We observed that traditional strategic frameworks often needed a modern lens to navigate the intricate execution challenges unique to complex life science environments.

This insight brought our team together with a singular mission: to empower leaders in the life sciences and technology sectors to thrive and lead, transforming their technical and scientific expertise into global impact.

Dexter Yan

Transformation and Operational Excellence
Dexter Yan specializes in Implementation at AGMI, where he co-leads the Firm's global implementation and transformation arms. He partners with senior leadership teams across life sciences and MedTech to diagnose operational inefficiencies and deliver high-impact solutions in strategic implementation, digital transformation, and supply chain optimization. He has over a decade of experience driving measurable improvements in performance, efficiency, and resilience throughout the healthcare value chain.

Prior to AGMI, Dexter was an Implementation Management Consultant at McKinsey & Company, where he conducted in-depth operational analyses for leading life sciences clients: designing and executing optimized drug manufacturing programs that significantly boosted annual throughput; enhancing MedTech supply chain strategies to drive On-Time In-Full performance; and rolling out tiered huddle structures to embed sustainable performance management. Earlier in his career, Dexter led strategic assessments for large biopharmaceutical organizations (identifying millions in potential FTE savings and crafting actionable roadmaps to optimize capacity) and directed enterprise-wide digital transformations, including digital performance management and Electronic Batch Record (EBR) systems, yielding significant efficiency gains, labor-cost savings, and reductions in non-conformances.

Dexter holds an MS in Plastics Engineering from the University of Massachusetts and a B Eng in Polymer Science and Engineering from the South China University of Technology.

Dr. Thong Cao

Transformation and GTM strategy
Thong is an Engagement Manager at AGMI, where he drives life-sciences portfolio strategy, private-equity advisory, and biopharma commercialization, delivering value through M&A, business-building, omnichannel go-to-market initiatives, and large-scale transformations. He partners with senior teams to design and execute high-impact commercialization roadmaps and value-creation programs across novel therapeutic modalities.

Prior to AGMI, Thong led formulation and drug-product development for cell and gene therapies at Sanofi, including autologous CD34+ stem-cell programs for sickle-cell disease. He also managed technical due diligence, IP strategy, and CDMO/CRO partnerships. At Caribou Biosciences, he co-led iPSC-CAR-NK development for solid tumors, established CDMO sourcing partnerships, and defined go-to-market strategies and pipeline business-development plans for next-generation cell therapies. Earlier in his career, Thong supported end-to-end cell and gene-therapy manufacturing operations, optimized pricing frameworks for specialty biologics, and guided CDMO/CRO selection to accelerate scale-up. His cross-functional expertise spans process development, commercialization strategy, and financial modeling to maximize pipeline value.

Thong holds a PhD in Biomedical Engineering from Cornell University and a BS in Biochemistry from the University of California, Davis.

Dr. Changho Yoon

AI deployment strategy
Changho leads the firm's AI and advanced analytics initiatives, applying advanced statistical and machine-learning methods to diverse data modalities to design and implement bespoke AI models, drive real-world evidence generation, and empower clients with AI literacy.

Prior to AGMI, Changho enjoyed a career as a physician-scientist with research in AI & health informatics, most recently at Oxford University Hospitals, Oxford University's Big Data Institute, the Turing Institute for AI (UK), and QuantumBlack (McKinsey & Co.). Through these experiences, he has engineered explainable causal-AI tools for healthcare clients, led the development of smartphone apps for hospital doctors, and secured over $1 million in research grants. Changho consults for biomedical AI start-ups, routinely translating between data scientists, engineers, clinicians, investors, and other stakeholders. He remains an active researcher and invited speaker/teaching faculty in biomedical AI, having co-authored papers in Nature and other top journals; he has been invited to speak and teach about AI methods at flagship institutions, like the World Health Organization and ETH Zürich.

Changho holds a PhD (DPhil) in Biomedical Statistics and Clinical Sciences from the Big Data Institute, University of Oxford; a Master of Biomedical Informatics from Harvard University & MIT; and an MD (MB BChir) and a BA in Natural Sciences from the University of Cambridge.

Dr. Bradley Chen

General Partner, Life Sciences & Healthcare
Dr. Bradley Chen is a General Partner at AGMI, where he advises biotech and healthcare companies on partnering strategy, corporate transformation, and cross-border growth. He works closely with boards, CEOs, and business development leaders to prepare assets and organizations for strategic collaborations and out-licensing, and to drive operational and commercial performance improvement across Taiwan, Japan, and the United States.

Prior to AGMI, Bradley served as VP of Strategy at Appier, a global AI SaaS company, where he led corporate strategy initiatives including partnership portfolio management, new product strategy, pricing optimization, and M&A due diligence and post-merger integration. Earlier, he was Taiwan Country Manager and VP of Asia Strategy at Rakuten Medical, where he established the Taiwan subsidiary and led regional strategy and execution, contributing to Japan’s conditional early approval of a first-in-class photoimmunotherapy for head and neck cancer.

Bradley began his career at McKinsey & Company as an Engagement Manager in the Life Sciences and Healthcare practices, advising global pharma, biotech, and healthcare organizations on corporate strategy and organizational transformation. He currently serves as an Independent Director of listed Taiwanese companies and holds adjunct academic appointments in health policy.

Bradley is a physician by training and holds a Doctor of Science from Harvard University, as well as an MPH from Harvard and an MD from National Taiwan University.

Annie Lin

Private capital
Annie Lin is Chief of Staff at AGMI, where she co-leads the firm's US strategic priorities with deep expertise in business management, corporate finance, value creation, M&A, and healthcare commercialization. In this capacity, she partners with senior leadership to bridge strategy and execution, driving cross-functional initiatives across sales & marketing, data analytics, value-creation programs, and internal transformation efforts. She oversees project governance, shapes organizational frameworks, and ensures cohesive execution of key firmwide and client-facing initiatives.

Prior to joining AGMI, Annie advised US healthcare businesses at a boutique investment bank, where she led deal valuations and due diligence for strategic M&A engagements. Earlier, as a Manager at HSBC, she managed banking relationships for hundreds of corporate clients, including screening high-conversion leads, reporting area deal pipelines that supported over $20 million in annual revenue, and stress-testing credit projections for complex financing arrangements. Throughout her career, Annie has published market insights to guide C-suite decision-making, managed client groups across AI, cloud/edge computing, and robotics/automation, and supported sell-side healthcare M&A through detailed financial modeling and bid analysis. Her thought leadership in digital transformation and process optimization has helped firms streamline operations, improve governance through robust KPI tools, and achieve significant efficiency enhancements and compliance enhancements.

Annie holds an MBA from UCLA Anderson School of Management and a BBA in Finance from National Taiwan University.

Lin-Ga Tsan

Sustainability
Lin-Ga is Co-Founder & General Partner (APAC) at AGMI, driving the firm's work with clients' cross-border expansion and strategic initiatives in the Asia-Pacific. His efforts often focus on guiding clients in U.S. market entry for Asian enterprises and Southeast Asian market development, particularly within advanced manufacturing and infrastructure development (electronics, electric mobility, Cleantech, AI Infrastructure, and renewable energy). His expertise combines corporate strategic planning, industry operations, and investment management, offering comprehensive advisory services to the firm's clients.

Lin-Ga has directly facilitated key cross-border successes, including guiding a prominent Taiwanese publicly traded manufacturer in acquiring U.S. companies (US$10M-100M) to expand its presence in the North American market, and enabling a major conglomerate to successfully establish a joint venture for renewable energy infrastructure (US$1.5B CapEx planned) in Southeast Asia.

Before co-founding AGMI, Lin-Ga's career was marked by impactful roles across leading global institutions. As Head of Business Portfolio & Strategy at Delta Energy Inc. (a subsidiary of Delta Electronics), he was pivotal in architecting US$2B in 10-year top-line growth strategies and forging global partnerships to expand the firm's product portfolio in Asia. As a Senior Strategy Consultant at IBM, he advised clients in manufacturing (high-tech, electronics), infrastructure and mobility (energy, EV, aerospace) industries, covering strategic projects including 5-year new business incubation, R&D roadmaps and product portfolio restructuring, supply chain relocations, and enterprise-grade AI and operation process automation implementation. His financial expertise was honed at J.P. Morgan's Hong Kong office, where he contributed to managing over US$1 billion in assets, delivering capital market solutions to PE/VC fund managers, family offices, and ultra-high-net-worth clients.

Lin-Ga holds dual bachelor's degrees in Energy Engineering and Economics from National Cheng-Kung University (NCKU), Taiwan. During his academic training, he served as a multi-year co-op researcher at the Intelligent Embedded Systems (IES) Lab at the Department of Aerospace & Aeronautics. He developed and deployed shop-floor AI and IoT solutions for OEM/ODM clients in the aerospace and defense sector. Beyond his professional endeavors, Lin-Ga is committed to fostering future cross-disciplinary business leaders in Asia. He co-founded the AAC Talent Hub, a dedicated initiative that has helped 1,000+ young professionals and entrepreneurs achieve their career aspirations.

Guan-Lun Liao

Co-Founder & US Managing Partner
Guan-Lun is a Co-Founder and leads the firm's US operations and initiatives – including startup advisory, new-venture development, and alternative-investment strategies – while acting as a bridge between scientific innovation and business execution.

Prior to co-founding AGMI, Guan-Lun was an operator-turned-investor who worked with venture-capital firms in Silicon Valley, New York, and Europe on AI and FinTech investments. He led due diligence on more than ten financings, backed early-stage startups as an angel investor, and advised over 30 companies on growth and fundraising strategy. He has also scaled venture-backed MedTech and Climate-Tech startups (helping to raise over $10 million in private funding and growing team sizes tenfold) by leading business development and operations. Earlier in his career, Guan-Lun drove product and project management for leading electronics conglomerates, overseeing half a dozen complex launches. He identified manufacturing process improvements, managed cross-functional teams to meet global client timelines, and later co-led engineering teams to bring three products to market, boosting production efficiency by double digits and halving installation failure rates.

Guan-Lun holds an MBA from the University of California, Berkeley's Haas School of Business, an MS in Quantitative Management from Duke University's Fuqua School of Business, and a BSc in Management Science from National Chiao Tung University.

Dr. Jean C. Cruz

Co-Founder & Global Managing Partner
Jean Cruz (JC) is the Global Managing Partner of AGMI, defining and driving the firm's strategic vision, operations, and growth across North America, Latin America, and Asia-Pacific. He is a trusted advisor to boards, CEOs, and private-equity investors in life sciences and healthcare, helping clients unlock differentiated growth, navigate complexity, and lead transformative R&D, clinical-trial acceleration, and M&A initiatives.

Prior to AGMI, JC was a Manager in McKinsey & Company's Life Sciences and Healthcare practices, where he led strategic and operational transformations for Fortune 500 pharma companies, biotech scale-ups, and private-equity funds. His work included designing pioneering R&D roadmaps for cell and gene therapies, optimizing clinical-trial processes, conducting buy- and sell-side due diligence across oncology, neuroscience, and rare-disease portfolios, and integrating data-driven market strategies.

Earlier in his career, JC completed a PhD in Biomedical Engineering (Applied Physics & Neuroscience), where his research produced several US patents, over $5 million in sponsored grants, and publications in Nature. He subsequently undertook postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School, pioneering neurodegenerative diagnostic and imaging platforms.

Leading up to his PhD at Cornell University, JC earned a BSc in Industrial Biotechnology and Chemical Engineering (Double Major) from Universidad de Puerto Rico.